Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Bevacizumab
Avastin · 7 trials · 7 indications
AUC0-infinity represents the area under the concentration-time curve of the analyte (5'-DFUR) in plasma over the time interval from 0 extrapolated to infinity. The analyte 5'-DFUR, the direct precursor of 5-fluorouracil (5-FU), is considered to be the most important metabolite of capecitabine in plasma. The unit of measure was nanograms per millilitre per hour (ng/mL \* hr).
AUC0-infinity represents the area under the concentration-time curve of the analyte (free platinum) in plasma over the time interval from 0 extrapolated to infinity. AUC0-inf for free platinum was calculated for each participant from the concentration-data obtained on Days 2 to 5 of Cycle 1, and Days 1 to 4 for Cycle 2 and 3. Free platinum is not bound to plasma proteins and is considered to be the most clinically significant measure of pharmacological and toxicological activity.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Avastin (bevacizumab) | DRUG | - |
| Tarceva (erlotinib HCl) | DRUG | - |
| Avastin | DRUG | 7.5mg/kg iv (cycle 3 only) |
| Oxaliplatin | DRUG | 130mg/m2 iv (cycles 1, 2 and 3) |
| capecitabine [Xeloda] | DRUG | 1000mg/m2 po bid (cycles 1, 2 and 3) |
Inclusion Criteria: * Written informed consent * Previous participation in and completion of one of the following Genentech-sponsored rhuMAb VEGF Phase II or Phase III cancer studies: AVF2107g, AVF2119g, or AVF2192g * Use of an effective means of contraception in men and in women of childbearing po...
Top 20 of 92 competitors
Avastin is used for treating colorectal cancer, renal cell carcinoma, breast cancer, non-small-cell lung carcinoma, and cancer generally. It is an investigational drug in Phase 3 clinical development for these oncology indications.
Avastin is a monoclonal antibody, classified as a -mab, that targets vascular endothelial growth factor. It is being studied for its role in inhibiting tumor growth in various cancers.
Avastin is developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's efficacy in multiple cancer types.
Avastin is in Phase 3 clinical development. It has completed three trials, including a Phase 3 study, and is not yet approved, meaning it remains investigational.
Avastin has been studied in three completed trials: NCT00095225 for non-small-cell lung carcinoma, NCT00096967 for breast and colorectal cancer, and NCT00109226 for metastatic colorectal cancer. These trials are all completed.
Yes, Avastin is also known as Bevacizumab. Both names refer to the same drug, and readers searching for either name will find information about this monoclonal antibody.